RANDAL J KIRK Insider Trading Transactions
Get free email notifications about insider trading for RANDAL J KIRK.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of RANDAL J KIRK. RANDAL J KIRK is Director in CLINICAL DATA INC ($NOVI) and 10% Owner in AmpliPhi Biosciences Corp ($APHB) and 10% Owner in Fibrocell Science, Inc. ($FCSC) and 10% Owner in SOLIGENIX, INC. ($DOR) and 10% Owner in Synthetic Biologics, Inc. ($SYN) and 10% Owner in TRANSGENOMIC INC ($TBIO) and Director in ZIOPHARM ONCOLOGY INC ($ZIOP) and 10% Owner in HALOZYME THERAPEUTICS INC ($GYHT) and Director in HALOZYME THERAPEUTICS INC ($GYHT) and 10% Owner in ORAGENICS INC ($OGEN) and 10% Owner in INTREXON CORP ($XON) and Chief Executive Officer in INTREXON CORP ($XON) and Director in INTREXON CORP ($XON) and Executive Chairman in INTREXON CORP ($XON) and 10% Owner in HISTOGENICS CORP ($HSGX) and 10% Owner in AquaBounty Technologies, Inc. ($AQB).
Latest Insider Trading Transactions of RANDAL J KIRK
Sentiment: All, AQB, APHB, NOVI, FCSC, GYHT, HSGX, OGEN, XON, PRPO, SNGX, SYN, ZIOP
Page: < prev 1 ... 2 3 4 5 6 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Mar 10 2017 | FCSC | Fibrocell Science, ... | KIRK RANDAL J | 10% Owner | Option Exercise | P | 0.85 | 2,250,594 | 1,903,777 | 2,250,594 | |
Mar 10 2017 | FCSC | Fibrocell Science, ... | KIRK RANDAL J | 10% Owner | Option Exercise | P | 0.85 | 3,867 | 3,271 | 3,867 | |
Mar 10 2017 | FCSC | Fibrocell Science, ... | KIRK RANDAL J | 10% Owner | Option Exercise | P | 0.85 | 136,634 | 115,579 | 136,634 | |
Mar 10 2017 | FCSC | Fibrocell Science, ... | KIRK RANDAL J | 10% Owner | Option Exercise | P | 0.78 | 1,161 | 901 | 1,496,529 | |
Mar 10 2017 | FCSC | Fibrocell Science, ... | KIRK RANDAL J | 10% Owner | Option Exercise | P | 0.78 | 1,746 | 1,354 | 2,250,594 | |
Mar 10 2017 | FCSC | Fibrocell Science, ... | KIRK RANDAL J | 10% Owner | Option Exercise | P | 0.78 | 3 | 2 | 3,867 | |
Mar 10 2017 | FCSC | Fibrocell Science, ... | KIRK RANDAL J | 10% Owner | Option Exercise | P | 0.78 | 106 | 82 | 136,634 | |
Mar 02 2017 | XON | INTREXON CORP | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,072 | 0 | 108,317 | |
Mar 02 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,072 | 0 | 108,317 | |
Mar 02 2017 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Gift | G | 0.00 | 200 | 0 | 5,315,445 | 5.3 M to 5.3 M (0.00 %) |
Mar 02 2017 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 22.26 | 8,984 | 199,984 | 5,315,645 | 5.3 M to 5.3 M (+0.17 %) |
Mar 02 2017 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 23.65 | 33,826 | 799,985 | 451,964 | 418.1 K to 452 K (+8.09 %) |
Feb 02 2017 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 21.16 | 9,451 | 199,983 | 5,306,661 | 5.3 M to 5.3 M (+0.18 %) |
Feb 02 2017 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 24.77 | 32,297 | 799,997 | 418,138 | 385.8 K to 418.1 K (+8.37 %) |
Feb 02 2017 | XON | INTREXON CORP | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,061 | 0 | 107,245 | |
Feb 02 2017 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,061 | 0 | 107,245 | |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 3,637 | 0 | 3,637 | 0 to 3.6 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 199,682 | 0 | 199,682 | 0 to 199.7 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 338,816 | 0 | 338,816 | 0 to 338.8 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 10,153 | 0 | 10,153 | 0 to 10.2 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 20,306 | 0 | 20,306 | 0 to 20.3 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 20,306 | 0 | 20,306 | 0 to 20.3 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 14,076 | 0 | 14,076 | 0 to 14.1 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 3,199 | 0 | 3,199 | 0 to 3.2 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 880 | 0 | 880 | 0 to 880 |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 82,083 | 0 | 82,083 | 0 to 82.1 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 99,537 | 0 | 99,537 | 0 to 99.5 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 295 | 0 | 295 | 0 to 295 |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 885 | 0 | 885 | 0 to 885 |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 1,770 | 0 | 1,770 | 0 to 1.8 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 2,021 | 0 | 2,021 | 0 to 2 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 12,617 | 0 | 12,617 | 0 to 12.6 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 1,132 | 0 | 1,132 | 0 to 1.1 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 12,726 | 0 | 12,726 | 0 to 12.7 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 10,784 | 0 | 10,784 | 0 to 10.8 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 1,708 | 0 | 1,708 | 0 to 1.7 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 2,095 | 0 | 2,095 | 0 to 2.1 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 2,080 | 0 | 2,080 | 0 to 2.1 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 20 | 0 | 20 | 0 to 20 |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 4,659 | 0 | 4,659 | 0 to 4.7 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 79,288 | 0 | 79,288 | 0 to 79.3 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 5,775 | 0 | 5,775 | 0 to 5.8 K |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Buy | P | 10.33 | 2,421,073 | 25,009,684 | 5,161,247 | 2.7 M to 5.2 M (+88.35 %) |
Jan 20 2017 | AQB | AquaBounty Technol ... | KIRK RANDAL J | 10% Owner | Sell | J | 0.00 | 1,776,557 | 0 | 2,740,174 | 4.5 M to 2.7 M (-39.33 %) |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 3,637 | 0 | 3,637 | 0 to 3.6 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 199,682 | 0 | 199,682 | 0 to 199.7 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 338,816 | 0 | 338,816 | 0 to 338.8 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 10,153 | 0 | 10,153 | 0 to 10.2 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 20,306 | 0 | 20,306 | 0 to 20.3 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 20,306 | 0 | 20,306 | 0 to 20.3 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 14,076 | 0 | 14,076 | 0 to 14.1 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 3,199 | 0 | 3,199 | 0 to 3.2 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 880 | 0 | 880 | 0 to 880 |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 82,083 | 0 | 82,083 | 0 to 82.1 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 99,537 | 0 | 99,537 | 0 to 99.5 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 295 | 0 | 295 | 0 to 295 |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 885 | 0 | 885 | 0 to 885 |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 1,770 | 0 | 1,770 | 0 to 1.8 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 2,021 | 0 | 2,021 | 0 to 2 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 12,617 | 0 | 12,617 | 0 to 12.6 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 1,132 | 0 | 1,132 | 0 to 1.1 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 12,726 | 0 | 12,726 | 0 to 12.7 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 10,784 | 0 | 10,784 | 0 to 10.8 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 1,708 | 0 | 1,708 | 0 to 1.7 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 2,095 | 0 | 2,095 | 0 to 2.1 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 2,080 | 0 | 2,080 | 0 to 2.1 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 20 | 0 | 20 | 0 to 20 |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 4,659 | 0 | 4,659 | 0 to 4.7 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 79,288 | 0 | 79,288 | 0 to 79.3 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | J | 0.00 | 5,775 | 0 | 5,775 | 0 to 5.8 K |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | P | 10.33 | 2,421,073 | 25,009,684 | 5,161,247 | 2.7 M to 5.2 M (+88.35 %) |
Jan 20 2017 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | J | 0.00 | 1,776,557 | 0 | 2,740,174 | 4.5 M to 2.7 M (-39.33 %) |
Dec 30 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,051 | 0 | 106,184 | |
Dec 30 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Grant | A | 0.00 | 17,204 | 0 | 139,513 | 122.3 K to 139.5 K (+14.07 %) |
Dec 30 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 24.30 | 8,230 | 199,989 | 5,297,210 | 5.3 M to 5.3 M (+0.16 %) |
Dec 30 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 28.38 | 28,188 | 799,975 | 385,841 | 357.7 K to 385.8 K (+7.88 %) |
Dec 30 2016 | XON | INTREXON CORP | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,051 | 0 | 106,184 | |
Dec 30 2016 | XON | INTREXON CORP | KIRK RANDAL J | Director | Grant | A | 0.00 | 17,204 | 0 | 139,513 | 122.3 K to 139.5 K (+14.07 %) |
Dec 29 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.45 | 20,077 | 9,035 | 674,169 | 694.2 K to 674.2 K (-2.89 %) |
Dec 29 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.47 | 40,450 | 19,012 | 694,246 | 734.7 K to 694.2 K (-5.51 %) |
Dec 29 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.51 | 24,092 | 12,287 | 734,696 | 758.8 K to 734.7 K (-3.18 %) |
Dec 29 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.45 | 21,923 | 9,865 | 736,170 | 758.1 K to 736.2 K (-2.89 %) |
Dec 29 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.47 | 44,170 | 20,760 | 758,093 | 802.3 K to 758.1 K (-5.51 %) |
Dec 29 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Sell | S | 0.51 | 26,308 | 13,417 | 802,263 | 828.6 K to 802.3 K (-3.18 %) |
Dec 29 2016 | APHB | AmpliPhi Bioscienc ... | KIRK RANDAL J | 10% Owner | Sell | S | 0.45 | 20,077 | 9,035 | 674,169 | 694.2 K to 674.2 K (-2.89 %) |
Dec 29 2016 | APHB | AmpliPhi Bioscienc ... | KIRK RANDAL J | 10% Owner | Sell | S | 0.47 | 40,450 | 19,012 | 694,246 | 734.7 K to 694.2 K (-5.51 %) |
Dec 29 2016 | APHB | AmpliPhi Bioscienc ... | KIRK RANDAL J | 10% Owner | Sell | S | 0.51 | 24,092 | 12,287 | 734,696 | 758.8 K to 734.7 K (-3.18 %) |
Dec 29 2016 | APHB | AmpliPhi Bioscienc ... | KIRK RANDAL J | 10% Owner | Sell | S | 0.45 | 21,923 | 9,865 | 736,170 | 758.1 K to 736.2 K (-2.89 %) |
Dec 29 2016 | APHB | AmpliPhi Bioscienc ... | KIRK RANDAL J | 10% Owner | Sell | S | 0.47 | 44,170 | 20,760 | 758,093 | 802.3 K to 758.1 K (-5.51 %) |
Dec 29 2016 | APHB | AmpliPhi Bioscienc ... | KIRK RANDAL J | 10% Owner | Sell | S | 0.51 | 26,308 | 13,417 | 802,263 | 828.6 K to 802.3 K (-3.18 %) |
Dec 14 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | P | 28.90 | 34,606 | 1,000,113 | 213,805 | 179.2 K to 213.8 K (+19.31 %) |
Dec 01 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,040 | 0 | 105,133 | |
Dec 01 2016 | XON | INTREXON CORP | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,040 | 0 | 105,133 | |
Dec 01 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 29.18 | 6,854 | 200,000 | 5,288,980 | 5.3 M to 5.3 M (+0.13 %) |
Dec 01 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 32.66 | 24,494 | 799,974 | 357,653 | 333.2 K to 357.7 K (+7.35 %) |
Nov 16 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Option Exercise | C | 0.00 | 2,142,857 | 0 | 0 | |
Nov 16 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | C | 0.00 | 428,571 | 0 | 828,571 | 400 K to 828.6 K (+107.14 %) |
Nov 16 2016 | APHB | AmpliPhi Bioscienc ... | KIRK RANDAL J | 10% Owner | Option Exercise | C | 0.00 | 2,142,857 | 0 | 0 | |
Nov 16 2016 | APHB | AmpliPhi Bioscienc ... | KIRK RANDAL J | 10% Owner | Buy | C | 0.00 | 428,571 | 0 | 828,571 | 400 K to 828.6 K (+107.14 %) |
Nov 02 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,030 | 0 | 104,093 | |
Nov 02 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 26.10 | 7,662 | 199,978 | 5,282,126 | 5.3 M to 5.3 M (+0.15 %) |
Nov 02 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 26.68 | 29,985 | 800,000 | 333,159 | 303.2 K to 333.2 K (+9.89 %) |
Nov 02 2016 | XON | INTREXON CORP | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,030 | 0 | 104,093 | |
Oct 04 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 28.02 | 7,137 | 199,979 | 5,274,464 | 5.3 M to 5.3 M (+0.14 %) |
Oct 04 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 27.44 | 29,154 | 799,986 | 303,174 | 274 K to 303.2 K (+10.64 %) |
Oct 04 2016 | XON | INTREXON CORP | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,020 | 0 | 103,063 | |
Oct 04 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,020 | 0 | 103,063 | |
Sep 09 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Option Exercise | P | 1.50 | 2,604,345 | 3,906,518 | 2,604,345 | |
Sep 09 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Option Exercise | P | 1.50 | 3,913,979 | 5,870,969 | 3,913,979 | |
Sep 09 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Option Exercise | P | 1.50 | 7,325 | 10,988 | 7,325 | |
Sep 09 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Option Exercise | P | 1.50 | 236,851 | 355,277 | 236,851 | |
Sep 09 2016 | FCSC | Fibrocell Science, ... | KIRK RANDAL J | 10% Owner | Option Exercise | P | 1.50 | 2,604,345 | 3,906,518 | 2,604,345 | |
Sep 09 2016 | FCSC | Fibrocell Science, ... | KIRK RANDAL J | 10% Owner | Option Exercise | P | 1.50 | 3,913,979 | 5,870,969 | 3,913,979 | |
Sep 09 2016 | FCSC | Fibrocell Science, ... | KIRK RANDAL J | 10% Owner | Option Exercise | P | 1.50 | 7,325 | 10,988 | 7,325 | |
Sep 09 2016 | FCSC | Fibrocell Science, ... | KIRK RANDAL J | 10% Owner | Option Exercise | P | 1.50 | 236,851 | 355,277 | 236,851 | |
Sep 02 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,010 | 0 | 102,043 | |
Sep 02 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 25.24 | 7,923 | 199,977 | 5,267,327 | 5.3 M to 5.3 M (+0.15 %) |
Sep 02 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 29.00 | 27,586 | 799,994 | 274,020 | 246.4 K to 274 K (+11.19 %) |
Aug 18 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Option Exercise | X | 3.18 | 2,957 | 9,403 | 0 | |
Aug 18 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Option Exercise | X | 2.65 | 8,871 | 23,508 | 0 | |
Aug 18 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | X | 3.18 | 2,957 | 9,403 | 5,259,404 | 5.3 M to 5.3 M (+0.06 %) |
Aug 18 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | X | 2.65 | 8,871 | 23,508 | 5,256,447 | 5.2 M to 5.3 M (+0.17 %) |
Aug 02 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 25.33 | 7,895 | 199,980 | 5,247,576 | 5.2 M to 5.2 M (+0.15 %) |
Aug 02 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 24.55 | 32,586 | 799,986 | 246,434 | 213.8 K to 246.4 K (+15.24 %) |
Aug 02 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | J | 0.00 | 1,033 | 0 | 101,033 | |
Jul 06 2016 | XON | INTREXON CORP | KIRK RANDAL J | Director | Option Exercise | P | 0.00 | 100,000 | 0 | 100,000 | |
Jul 06 2016 | ZIOP | ZIOPHARM ONCOLOGY ... | KIRK RANDAL J | Director | Option Exercise | P | 0.00 | 100,000 | 0 | 100,000 | |
Jul 05 2016 | XON | INTREXON CORP | KIRK RANDAL J | 10% Owner | Buy | P | 0.52 | 2,261,419 | 1,166,666 | 14,481,089 | 12.2 M to 14.5 M (+18.51 %) |
Jul 05 2016 | OGEN | ORAGENICS INC | KIRK RANDAL J | 10% Owner | Buy | P | 0.52 | 2,261,419 | 1,166,666 | 14,481,089 | 12.2 M to 14.5 M (+18.51 %) |
Jul 01 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 24.61 | 8,126 | 199,981 | 5,239,681 | 5.2 M to 5.2 M (+0.16 %) |
Jul 01 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Grant | A | 25.50 | 31,372 | 799,986 | 213,848 | 182.5 K to 213.8 K (+17.19 %) |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 21,858 | 0 | 21,858 | 0 to 21.9 K |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 65,572 | 0 | 65,572 | 0 to 65.6 K |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 131,144 | 0 | 131,144 | 0 to 131.1 K |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 4,382 | 0 | 46,701 | 42.3 K to 46.7 K (+10.35 %) |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 27,260 | 0 | 290,460 | 263.2 K to 290.5 K (+10.36 %) |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 2,235 | 0 | 2,235 | 0 to 2.2 K |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 23,259 | 0 | 354,653 | 331.4 K to 354.7 K (+7.02 %) |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 23,259 | 0 | 354,654 | 331.4 K to 354.7 K (+7.02 %) |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 9,954 | 0 | 302,954 | 293 K to 303 K (+3.40 %) |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 9,954 | 0 | 302,954 | 293 K to 303 K (+3.40 %) |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 9,954 | 0 | 302,954 | 293 K to 303 K (+3.40 %) |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 372 | 0 | 11,317 | 10.9 K to 11.3 K (+3.40 %) |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 371,186 | 0 | 3,056,601 | 2.7 M to 3.1 M (+13.82 %) |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Buy | J | 0.00 | 81,795 | 0 | 216,795 | 135 K to 216.8 K (+60.59 %) |
Jun 02 2016 | GYHT | HALOZYME THERAPEUT ... | KIRK RANDAL J | Director | Sell | J | 0.00 | 1,326,320 | 0 | 0 | 1.3 M to 0 (-100.00 %) |
Jun 02 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 19,711 | 0 | 19,711 | 0 to 19.7 K |
Jun 02 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 59,133 | 0 | 59,133 | 0 to 59.1 K |
Jun 02 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 118,266 | 0 | 118,266 | 0 to 118.3 K |
Jun 02 2016 | XON | INTREXON CORP | KIRK RANDAL J | Chief Executive Off ... | Buy | J | 0.00 | 3,952 | 0 | 135,033 | 131.1 K to 135 K (+3.01 %) |